The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
|Podcasts|April 10, 2019
Highlighting Breakthroughs in Breast Cancer in Nashville
Author(s)Onclive Team
We traveled to Nashville, Tennessee, for a State of the Science Summit™ on Breast Cancer, which focused on some of the practice-changing updates that have been occurring in the field.
Advertisement
We recently ventured to Nashville, Tennessee for a State of the Science Summit™ on Breast Cancer. At this conference, we sat down with faculty from Sarah Cannon Research Institute, HCA Midwest Health, Virginia Cancer Specialists, and Memorial Sloan Kettering Cancer Center to discuss some of the practice-changing updates that have been occurring in the field.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Advertisement
Advertisement
Trending on OncLive
1
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
2
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
3
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
4
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
5